TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05681260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone,Vincristine, Pegylated-asparaginase, Bortezomib,Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine, methotrexate, Dexamethasone, Doxorubicin
Description: Standard risk Arm A: Induction I followed by Consolidation, extracompartmental Capizzi MTX, delayed intensification and 96 weeks' maintenance therapy. Twenty-one or twenty-six triple intrathecal injections for CNS negative or positive patients, respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone,Vincristine, Pegylated-asparaginase, Bortezomib,Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine, methotrexate, Dexamethasone, Doxorubicin
Description: Standard risk Arm B: Induction I followed by Consolidation, extracompartmental high dose MTX, delayed intensification and 96 weeks' maintenance therapy. Twenty-one or twenty-six triple intrathecal injections for CNS negative or positive patients, respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone,Vincristine, Pegylated-asparaginase, Bortezomib,Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine, methotrexate, Dexamethasone, Doxorubicin, Vindesine, Etoposide, Ifosfamide
Description: High Risk T-LBL: Induction I followed by 2 cycles of BFM HR Blocks, delayed intensification and 96 weeks' maintenance therapy. Twenty-four or twenty-eight triple intrathecal injections for CNS negative or positive patients, respectively.
Study: NCT05575908

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Digital expert team
Description: A digital team will be appointed based on the participant's answers in the digital screening questionnaire. Members of the team can be specialists in Physical and rehabilitation medicine, psychologist, physiotherapist, social workers, and consultants in the labor- and welfare administration. The general practitioner will also be invited to the meeting.
Study: NCT05102383

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comfilcon A Toric contact lenses
Description: Monthly replacement contact lenses

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Verofilcon A for Astigmatism Daily Disposable contact lenses
Description: Daily disposable contact lenses
Study: NCT05227794

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compassion Cultivation Training (CCT)
Description: CCT is a secular, empirically supported 8-week program that integrates meditation practices, interactive discussions, and educational lectures to improve self-compassion and other-oriented compassion, emotion and stress management, and happiness and well-being. It includes a weekly 2-hour educational lecture with discussion and in-class exercises, a recommendation of 15-30 minutes of daily meditation, and real-world assignments to practice compassion. The program is taught by a certified instructor with more than 5 years experience.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Description: MBSR is among the most studied mindfulness-based interventions in the literature and is a secular, 8-week psycho-educational group-based intervention. The program structure (slightly modified to match CCT) includes a weekly 2-hour class, a prescription of 15-30-minutes of daily mindfulness practice, and a one-day optional retreat (6 hours) between week six and seven. The program is taught by a certified instructor with more than 5 years experience.
Study: NCT05774158

Intervention type: OTHER
Intervention: Physiotherapy assessment
Description: Of the individuals included in the study; Information about age, height, body weight, type of congenital heart disease, surgical history, drug use, comorbid chronic disease, education level and occupation will be obtained. Functional Capacity, Peripheral Muscular Strength, Hand Grip Strength, Fatigue, Physical Activity Level, Quality of Life, Social Participation, Depression Anxiety Stress Level and Physical Activity Barriers will be evaluated
Study: NCT06207773

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educator verbal feedback
Description: the educator will hold one-on-one meetings with the students regarding their clinical internship for at least 20 minutes every week for a total of 6 weeks. Within the scope of this interview, the educator will give verbal feedback about the strengths and development aspects of the student's diagnosis, planning, implementation, evaluation stages and clinical skills in line with the nursing care plan. In addition, if there are clinical assignments (such as case analysis) given to the student, the educator will give feedback on this subject as well.
Study: NCT04528433

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: routine clinical care
Description: Routine clinical care includes a structured family behavioral intervention for ADHD symptom management and organizational skill training, the medication will be used if necessary.
Study: NCT05807815

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Titration of fraction of inspired oxygen (FiO2) guided by ORI and oxygen saturation
Description: FiO2 will be titrated by reducing 10% if Ori\>0.01 and oxygen saturation ≥ 98% until Ori is 0.00.~FiO2 will not be changed if Ori is 0.00 and %95\<oxygen saturation≤%98 FiO2 will be increased by 10% if oxygen saturation \<95 or PaO2\<60 mmHg
Study: NCT06403735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLC1101
Description: QLC1101 is an innovative small molecule inhibitor targeting KRAS G12D with independent intellectual property rights developed by Qilu Pharmaceutical Co., Ltd.QLC1101 can prevent GTP/GDP nucleotide exchange and/or the formation of KRAS G12D/GTP/RAF1 complex and inhibit mutant KRAS-dependent signal transduction by specifically binding to the KRAS G12D target, thereby inhibiting the generation of KRAS G12D mutant tumors.
Study: NCT05762900

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultra-fractionated radiation therapy
Description: 5.2Gy per fraction for 5 fractions with an integrated boost of 6Gy per fraction.
Study: NCT05130931

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal conservative treatment
Description: 15 min of Pain education + 20 min of Specific mobilization of the forearm musculature, pronator teres, tendons of the palmar flexors of the wrist and fingers, transverse carpal ligament and palmar fascia through manual mobilization assisted by Diacutaneous Fibrolysis technique + 10min of self-management and explanation of home-based exercise.~3 sessions of 45 minutes will be taken to perform this protocol and the patient will be shown a self-treatment to be performed 3-5 times a day. The protocol will be carried out over 3 weeks (1 session per week).
Study: NCT06412952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-RM26
Description: Intravenous injection of one dosage of 74-185 MBq(2-5 mCi) 68Ga-RM26. Tracer doses of 68Ga- RM26 will be used to image lesions of glioma by PET/CT.
Study: NCT05147493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Route of administration: Intravenous (IV). Dose regimen: Isatuximab will be given at a dose of 10 mg/kg once weekly (QW) on Days 1, 8, 15, and 22 in Cycle 1, on Days 1 and 15 during Cycles 2-6 and on Day 1 from Cycle 7 onwards.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Route of administration: Subcutaneous (SC). Dose regimen: Bortezomib will be given at 1.3 mg/m2 on Days 1, 4, 8, 11 of Cycle 1 and days 1, 8, 15, 22 of Cycles 2-6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Route of administration: Intravenous (IV). Dose regimen: Cyclophosphamide will be given at 300 mg/m2on Days 1, 8, 15 of Cycle 1 and days 1, 8, 15, 22 of Cycles 2-6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Route of administration: per os (PO)/Intravenous (IV). Dose regimen: Dexamethasone will be given at 40 mg (20 mg for ≥75 years old) on Days 1-4 and 9-12 of Cycle 1 and Days 1, 8, 15 and 22 of Cycles 2-6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Route of administration: per os (PO). Dose regimen: Lenalidomide will be given at 10 mg (or according to renal function) daily from Cycle 7 onwards.
Study: NCT04881708

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Remote Monitoring
Description: Subjects assigned to the Remote Care group will receive education from a clinical nurse from Mayo Clinic's Department of Connected Care on use of the equipment as part of Remote Monitoring. The equipment will be shipped along with instructions and Welcome Letter describing the Mayo Clinic Remote Patient Monitoring program. The Remote Patient Monitoring kit includes a digital tablet, a blood pressure cuff, a thermometer, a pulse oximeter, and a weight scale. Subjects will be contacted by phone at the end of the study to be instructed how to return the kit by mail.
Study: NCT05583149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACALABRUTINIB
Description: Oral, twice daily, timing and dosage per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LISOCABTAGENE MARALEUCEL
Description: via IV timings and dosage per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lymphodepleting chemotherapy
Description: lymphodepleting chemotherapy with cyclophosphamide and fludarabine once a day for 3 days via IV about 2-4 hours. This will occur only once prior to lisocabtagene maraleucel infusion.
Study: NCT05793606

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deltoid ligament repair
Description: Surgical repair for the deltoid ligament
Study: NCT06046456

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prenatal Affective CogntiiveTraining
Description: A psychological intervention using computer- and virtual reality based exercises to modify negative cognitive bias and improve emotion regulation
Study: NCT05623215

Intervention type: RADIATION
Intervention: Radiographs of the knee for radiostereometric analysis (RSA)
Description: RSA radiographs will be made 5 and 10 years after the total knee arthroplasty.

Intervention type: RADIATION
Intervention: Radiographs of the knee for radiostereometric analysis (RSA)
Description: RSA radiographs will be made 5 and 10 years after the total knee arthroplasty.
Study: NCT04679909

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCOVID
Description: Administered intranasally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCOVID
Description: Administered intranasally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCOVID
Description: Administered intranasally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCOVID
Description: Administered intranasally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCOVID
Description: Administered intranasally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCOVID
Description: Administered intranasally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered intranasally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered intranasally
Study: NCT04787380

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heartfelt device
Description: The Heartfelt device uses a system of cameras in a compact device to generate 3D images of the feet and lower legs with a view to detecting early volume changes. The device can be installed on the wall or as a free standing unit; however, given the COVID-19 pandemic, only the free standing option will be available to participants, so as to avoid the necessity of an installer visiting the patient. For the measurements to take place, the participant walks in the field of view of the device. Participants are not expected to change anything to their routine. The device can also take measurements in the dark.~The switch between 'full data analysis' and 'technical checks only' modes can be done remotely, making the cross-over seamless.~In the event that an alert is generated by the device, a medical assessment will take place either by phone or face to face appointment to evaluate the participant's condition.
Study: NCT05296980

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REMINDER
Description: The REMINDER program is a therapist-mediated manualized neuropsychological intervention, involving training skills to stimulate cognitive reserve, socialization and personal development, to diminish the risk of cognitive decline.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REMINDER
Description: The REMINDER program is a therapist-mediated manualized neuropsychological intervention, involving training skills to stimulate cognitive reserve, socialization and personal development, to diminish the risk of cognitive decline.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Brain health Psychoeducation
Description: Delivery of psychoeducation sessions about dementia modifiable risk factors, brain health solutions and lifestyle change tips.
Study: NCT05549154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose vitamin D2 softgels
Description: 5000U/capsule of vitamin D2 soft capsule; High-dose VD group 50,000 U/week, 5 vitamin D2 softgels given twice a week each time; 25(OH)D \> 80ng/ml after 3 months of intervention or within 3 months in both groups, changed to 5,000 U/ weekly maintenance until the full 6 months of intervention. To prevent unmasking, the maintenance dose was still given twice weekly (the first time 1 vitamin D2 capsule + 4 placebo capsules were given and the second time 5 placebo capsules were given)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low-dose vitamin D2 softgels
Description: 5000U/capsule of vitamin D2 soft capsule; low-dose VD group 25,000 U/week, 3 vitamin D2 softgels + 2 placebo in the first dose, 2 vitamin D2 softgels + 3 placebo in the second dose, 25(OH)D \> 80ng/ml after 3 months of intervention or within 3 months in both groups, changed to 5,000 U/ weekly maintenance until the full 6 months of intervention. To prevent unmasking, the maintenance dose was still given twice weekly (the first time 1 vitamin D2 capsule + 4 placebo capsules were given and the second time 5 placebo capsules were given);

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo was filled with excipients (aniseed ether, refined vegetable oil), and the shape and size were the same as vitamin D2 soft capsule.the control group was given placebo, 5 placebo capsules twice weekly for 6 months of the intervention. The medication was dispensed by a designated person (not the investigator) in advance and independently according to the patient's medication number (only the drug number was provided on the outer packaging).
Study: NCT04722757

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ta-IPAA
Description: A trans-anal port (gelpoint path, Applied Medical®) will be used for transanal acces and pneumopelvis will be created. The initial purse string is to be placed approximately 3cm above the dentate line, followed by a rectotomy. The perirectal dissection is then continued and should be pursued for at least 5cm. More proximal dissection can be done by transabdominal access. After completion of the proctectomy, a double purse string anastomosis is performed after creation of the J-pouch. A defunctioning loop ileostomy can be placed according to surgeon's preference.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tabd-IPAA
Description: Patients in the control group will undergo a rectal dissection by laparotomy, Pfannenstiel incision, (hand-assisted) laparoscopy, single port laparoscopy or robotic surgery, but performed from the abdominal side (tabd-IPAA). Dissection will be performed down to the pelvic floor and include the distal rectum. It is anticipated that most dissection will occur using the TME plane, however, close rectal dissection is also acceptable. Transection of the distal rectum approximately 2 cm above the dentate line will be performed using a linear stapler of the surgeon's choice. After placing the anvil in the J-pouch, a circular stapler will be introduced through the sphincter and a circular anastomosis will be performed. A defunctioning loop ileostomy can be placed according at the surgeon's discretion.
Study: NCT06272032

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High-intensity focused ultrasound (HIFU)
Description: Ultrasound is a type of mechanical vibrational wave capable of penetrating living tissues without causing harm to the tissue. As a non-invasive physical modality, ultrasound boasts advantages such as non-invasive safety, excellent directional propagation, strong penetration capability, and optimal focusing effects. It can induce a series of structural and functional changes in tissue cells through actions like cavitation, mechanical force vibration, and heat generation, leading to corresponding clinical effects. Clinical studies have demonstrated that focused ultrasound not only improves symptoms of allergic rhinitis (AR) but also holds certain advantages in preserving the structural and functional integrity of the nasal mucosa.
Study: NCT06202391

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autogenic Inhibition-MET
Description: Autogenic Inhibition-MET protocol: 3-5 repetitions of post isometric relaxation (PIR) (30- 50% isometric contraction of the muscle to be stretched for 5-10 seconds, followed by rest period of 5 seconds and then a stretch of 20-30 seconds' hold. A total of 12 sessions, four times a week, for three consecutive weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reciprocal Inhibition-MET protocol
Description: Reciprocal Inhibition-MET protocol: 3-5 repetitions of Reciprocal Inhibition (RI) MET (30- 50% isometric contraction of the muscle opposite to the muscle to be stretched for 5-10 seconds, followed by rest period of 5 seconds and then a stretch of 20-30 seconds' hold A total of 12 sessions, four times a week, for three consecutive weeks
Study: NCT05803239

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EBUS-TBNA
Description: Participants with lymphadenopathy would receive EBUS-TBNA attempts to conduct diagnoses.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EBUS-TBNA
Description: Participants with lymphadenopathy would receive EBUS-TBNA attempts to conduct diagnoses.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EBUS-TBMC via a tunnel
Description: Participants with lymphadenopathy would receive EBUS-TBMC via a tunnel attempts to conduct diagnoses.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EBUS-TBMC via a tunnel
Description: Participants with lymphadenopathy would receive EBUS-TBMC via a tunnel attempts to conduct diagnoses.
Study: NCT06320145

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: This device used at the first, second and third day of period to decrease pain for 20 min at first, second and third day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: core stability exercises
Description: core stability exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: core stability exercises
Description: core stability exercises
Study: NCT05985655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTAEXS617
Description: GTAEXS617 tablets daily
Study: NCT05958355

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional postural control training
Description: All participants will receive functional postural control training for 30 minutes/ session, 3 sessions/ weeks, for 4 weeks (a total of 12 training sessions).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill training
Description: All participants will receive treadmill training for 30 minutes/ session, 3 sessions/ weeks, for 4 weeks (a total of 12 training sessions).
Study: NCT06272032

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intranasal corticosteroids, oral antihistamines, oral leukotriene receptor antagonists, and intranasal antihistamines
Description: intranasal corticosteroids, oral antihistamines, oral leukotriene receptor antagonists, and intranasal antihistamines and other therapies.
Study: NCT06377137

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Small-sided soccer games groups (SSSG)
Description: Physical exercise intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Traditional soccer training groups (TSG)
Description: Physical exercise intervention
Study: NCT05395299

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SQUID (Ethylene Vinyl Alcohol Copolymer ) administred to the participant with the intervention Prostatic Arterial Embolization
Description: Prostatic Arterial Embolization with SQUID (Ethylene Vinyl Alcohol Copolymer )
Study: NCT06035354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK120
Description: subcutaneous injection once a week
Study: NCT06125730

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DIME Beauty Eyelash Boost Serum
Description: The test product contains Water, Glycerin, Amino Acids (Sodium PCA, Sodium Lactate, Arginine, Aspartic Acid, PCA, Glycine, Alanine, Serine, Valine, Proline, Threonine, Isoleucine, Histidine, Phenylalanine), Hyaluronic Acid, Panthenol, Aloe Leaf Extract, Niacinamide, Purslane, Chebulic Fruit Extract, Apple Fruit Extract, Tocopherol, Phenoxyethanol, Hexanediol, Ethylhexylglycerin, Biotinoyl Tripeptide-1, Myristoyl Pentapeptide-4.
Study: NCT04727801

Intervention type: DEVICE
Intervention: Verily Patch
Description: The Verily Patch is an investigational wearable temperature sensor that consists of a Patch (Verily Patch), with swappable adhesives, as well as an app (Verily Patch app).

Intervention type: DEVICE
Intervention: Verily Patch
Description: The Verily Patch is an investigational wearable temperature sensor that consists of a Patch (Verily Patch), with swappable adhesives, as well as an app (Verily Patch app).
Study: NCT05739149

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Microvessel Ultrasound Examination
Description: Ultrasound to evaluate microvessel formation and elastography or stiffness of the tissues around the ulcer and in an area of unaffected skin

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin Biopsy
Description: Dermatology will remove a small piece of skin from the affected ulcer area and control skin
Study: NCT06035354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK120
Description: subcutaneous injection once a week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous injection once a week.
Study: NCT06355024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inosine
Description: oral inosine 200mg tid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum
Description: Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum